

Roseann S Gammal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1220886/publications.pdf>

Version: 2024-02-01

30
papers

1,917
citations

623734

14
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

2083
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardizing <i><scp>CYP</scp>2D6</i> Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. <i>Clinical and Translational Science</i> , 2020, 13, 116-124.	3.1	353
2	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	4.7	211
3	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 171-175.	4.7	207
4	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 599-618.	4.7	186
5	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2C19</i> Genotype and Clopidogrel Therapy: 2022 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 959-967.	4.7	166
6	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>UGT1A1</i> and Atazanavir Prescribing. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 363-369.	4.7	161
7	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1417-1423.	4.7	157
8	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz-Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	4.7	125
9	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1977-1985.	1.0	79
10	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. <i>Pediatrics</i> , 2016, 138, .	2.1	71
11	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 303-313.	1.0	45
12	Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 646-650.	1.5	29
13	A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 50-52.	4.7	22
14	Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics. <i>American Journal of Pharmaceutical Education</i> , 2022, 86, 8634.	2.1	21
15	Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 409-415.	1.0	14
16	The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1300-1302.	4.7	12
17	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 288-302.	1.0	10
18	Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams. <i>Journal of Personalized Medicine</i> , 2021, 11, 1296.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Advanced Pharmacy Practice Experiences in Pharmacogenomics Offered by US Pharmacy Programs. American Journal of Pharmaceutical Education, 2020, 84, ajpe8031.	2.1	8
20	Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events. Drug Safety, 2021, 44, 601-607.	3.2	6
21	Considerations for pharmacogenomic testing in a health system. Genetics in Medicine, 2019, 21, 1886-1887.	2.4	5
22	Pharmacogenetics: A precision medicine approach to combatting the opioid epidemic. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 239-250.	1.0	5
23	The essential research curriculum for doctor of pharmacy degree programs â€“ 2021. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	4
24	The pharmacist's responsibility to ensure appropriate use of direct-to-consumer genetic testing. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 652-658.	1.0	4
25	Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection. American Journal of Health-System Pharmacy, 2014, 71, 204-208.	1.0	3
26	Key considerations for using pharmacogenomics to optimize pain management. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 290-291.	1.5	2
27	Heterokaryon Technique for Analysis of Cell Type-specific Localization. Journal of Visualized Experiments, 2011, , .	0.3	1
28	Ambulatory Care Training Within Postgraduate Year 2 Pediatric Pharmacy Residency Programs. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 214-219.	0.5	1
29	Leveraging precision medicine to mitigate medication-safety challenges. American Journal of Health-System Pharmacy, 2017, 74, 2031-2032.	1.0	0
30	P256. ABCB1 Gene Variants and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis Including Results From the CAN-BIND-1 Cohort. Biological Psychiatry, 2022, 91, S191.	1.3	0